Published in Vaccine on January 31, 2009
Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr (2013) 0.96
Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. PLoS One (2012) 0.91
Seroprevalence of pertussis in China: need to improve vaccination strategies. Hum Vaccin Immunother (2013) 0.84
Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States. Am J Epidemiol (2016) 0.83
Modelling the return on investment of preventively vaccinating healthcare workers against pertussis. BMC Infect Dis (2015) 0.75
Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog (2005) 2.71
Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol (2004) 2.58
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis (2010) 2.48
Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02
Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis (2013) 1.91
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J (2008) 1.69
Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One (2010) 1.61
Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis (2012) 1.50
Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (2002) 1.46
Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine (2008) 1.39
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
[High vaccination coverage of the National Immunization Programme in the Netherlands]. Ned Tijdschr Geneeskd (2009) 1.30
Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine (2013) 1.24
Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci (2005) 1.24
Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One (2010) 1.15
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J (2006) 1.14
Improving pertussis vaccination. Hum Vaccin (2009) 1.12
Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine (2010) 1.10
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09
Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine (2012) 1.09
Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol (2007) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin (2006) 1.03
Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis (2010) 1.03
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine (2011) 1.03
Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine (2004) 1.02
Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine (2010) 1.01
Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine (2007) 1.00
Why parents refuse childhood vaccination: a qualitative study using online focus groups. BMC Public Health (2013) 1.00
The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol (2008) 0.99
Pertussis: a matter of immune modulation. FEMS Microbiol Rev (2011) 0.99
HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer (2009) 0.99
Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr (2013) 0.96
An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine (2009) 0.96
Underreporting of meningococcal disease incidence in the Netherlands: results from a capture-recapture analysis based on three registration sources with correction for false positive diagnoses. Eur J Epidemiol (2006) 0.93
Hospitalization due to varicella in the Netherlands. BMC Infect Dis (2011) 0.93
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol (2012) 0.92
Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One (2011) 0.91
The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif (2005) 0.91
Factors that influence vaccination decision-making by parents who visit an anthroposophical child welfare center: a focus group study. Adv Prev Med (2012) 0.91
Valganciclovir for Congenital Cytomegalovirus. N Engl J Med (2015) 0.91
Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine (2006) 0.91
Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: the H2M study. Cancer Epidemiol Biomarkers Prev (2013) 0.90
Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun (2004) 0.90
Estimation of household transmission rates of pertussis and the effect of cocooning vaccination strategies on infant pertussis. Epidemiology (2012) 0.90
Acceptance of vaccination during pregnancy: experience with 2009 influenza A (H1N1) in the Netherlands. Vaccine (2012) 0.90
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention. Int J Cancer (2012) 0.89
Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res (2010) 0.89
Association of Bordetella pertussis with host immune cells in the mouse lung. Microb Pathog (2003) 0.88
Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol (2013) 0.88
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008. Vaccine (2012) 0.86
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands. Emerg Infect Dis (2015) 0.85
Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine (2006) 0.85
Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis (2008) 0.85
Parental information-seeking behaviour in childhood vaccinations. BMC Public Health (2013) 0.85
Participation in and attitude towards the national immunization program in the Netherlands: data from population-based questionnaires. BMC Public Health (2012) 0.84
An exploratory qualitative assessment of factors influencing childhood vaccine providers' intention to recommend immunization in the Netherlands. BMC Public Health (2012) 0.84
Estimating the incidence of subclinical infections with Legionella Pneumonia using data augmentation: analysis of an outbreak in The Netherlands. Stat Med (2003) 0.84
Psychosocial determinants of parents' intention to vaccinate their newborn child against hepatitis B. Vaccine (2012) 0.83
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol (2007) 0.83
Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum Vaccin Immunother (2012) 0.82
Delayed start of diphtheria, tetanus, acellular pertussis and inactivated polio vaccination in preterm and low birth weight infants in the Netherlands. Pediatr Infect Dis J (2014) 0.81
Bordetella pertussis isolates, Finland. Emerg Infect Dis (2005) 0.81
Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol (2013) 0.81
Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands. BMC Public Health (2014) 0.81
Whooping cough in Pakistan: Bordetella pertussis vs Bordetella parapertussis in 2005-2009. Scand J Infect Dis (2011) 0.81
Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection. BMC Microbiol (2007) 0.81
Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. AIDS (2013) 0.81
Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine (2013) 0.80
Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands. PLoS One (2012) 0.80
The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine (2007) 0.80
Complement evasion by Bordetella pertussis: implications for improving current vaccines. J Mol Med (Berl) (2015) 0.80
Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands. Am J Epidemiol (2014) 0.79
Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin. Clin Infect Dis (2009) 0.78
Molecular typing of Bordetella parapertussis isolates circulating in Pakistan. FEMS Immunol Med Microbiol (2011) 0.78
Economic Costs of Measles Outbreak in the Netherlands, 2013-2014. Emerg Infect Dis (2015) 0.77
Investment in antiviral drugs: a real options approach. Health Econ (2010) 0.77
Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children. Vaccine (2011) 0.77
Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factor. FEMS Immunol Med Microbiol (2007) 0.77